<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of inserm-00446432</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-17T04:19:18+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">[Bispecific antibodies: what future?]</title>
            <author role="crp">
              <persName>
                <forename type="first">André</forename>
                <surname>Pèlegrin</surname>
              </persName>
              <email type="md5">cef2cab8c20d33e9745fa7c723931251</email>
              <email type="domain">inserm.fr</email>
              <idno type="idhal" notation="string">andre-pelegrin</idno>
              <idno type="idhal" notation="numeric">176279</idno>
              <idno type="halauthorid" notation="string">2764-176279</idno>
              <idno type="RESEARCHERID">http://www.researcherid.com/rid/J-3167-2016</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-9254-2648</idno>
              <idno type="RESEARCHERID">http://www.researcherid.com/rid/http://www.researcherid.com/rid/J-3167-2016</idno>
              <affiliation ref="#struct-55685"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Bruno</forename>
                <surname>Robert</surname>
              </persName>
              <idno type="idhal" notation="numeric">755892</idno>
              <idno type="halauthorid" notation="string">119786-755892</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-5999-4538</idno>
              <idno type="IDREF">https://www.idref.fr/081115822</idno>
              <affiliation ref="#struct-55685"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Yves</forename>
                <surname>Le Ster</surname>
              </persName>
              <email type="md5">26a6def8078afcdd00d94ecde4e470ca</email>
              <email type="domain">inserm.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2010-06-01 08:33:33</date>
              <date type="whenModified">2024-10-22 12:18:03</date>
              <date type="whenReleased">2010-01-14 15:59:22</date>
              <date type="whenProduced">2009-12</date>
              <date type="whenEndEmbargoed">2010-06-01</date>
              <ref type="file" target="https://inserm.hal.science/inserm-00446432v1/document">
                <date notBefore="2010-06-01"/>
              </ref>
              <ref type="file" subtype="author" n="1" target="https://inserm.hal.science/inserm-00446432v1/file/BAbs_quel_avenir_Pelegrin_090223.pdf" id="file-446432-358013">
                <date notBefore="2010-06-01"/>
              </ref>
              <ref type="externalLink" target="https://www.medecinesciences.org/articles/medsci/pdf/2009/12/medsci20092512p1155.pdf"/>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="117651">
                <persName>
                  <forename>Yves</forename>
                  <surname>Le Ster</surname>
                </persName>
                <email type="md5">26a6def8078afcdd00d94ecde4e470ca</email>
                <email type="domain">inserm.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">inserm-00446432</idno>
            <idno type="halUri">https://inserm.hal.science/inserm-00446432</idno>
            <idno type="halBibtex">pelegrin:inserm-00446432</idno>
            <idno type="halRefHtml">&lt;i&gt;Médecine/Sciences&lt;/i&gt;, 2009, 25 (12), pp.1155-8. &lt;a target="_blank" href="https://dx.doi.org/10.1051/medsci/200925121155"&gt;&amp;#x27E8;10.1051/medsci/200925121155&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Médecine/Sciences, 2009, 25 (12), pp.1155-8. &amp;#x27E8;10.1051/medsci/200925121155&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-446432-358013"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="INSERM">INSERM - Institut national de la santé et de la recherche médicale</idno>
            <idno type="stamp" n="UNIV-MONTP1">Université Montpellier I</idno>
            <idno type="stamp" n="M-S" corresp="INSERM">Médecine Sciences</idno>
            <idno type="stamp" n="FNCLCC" corresp="INSERM">UNICANCER</idno>
            <idno type="stamp" n="VALDAURELLE" corresp="FNCLCC">CRLC Val d'Aurelle - Paul Lamarque</idno>
            <idno type="stamp" n="BS">Biologie-Santé</idno>
            <idno type="stamp" n="UNIV-MONTPELLIER">Université de Montpellier</idno>
            <idno type="stamp" n="IRCM" corresp="UNIV-MONTPELLIER">Institut de Recherche en Cancérologie de Montpellier</idno>
            <idno type="stamp" n="UM1-UM2" corresp="UNIV-MONTPELLIER">Université Montpellier 1 - Université Montpellier 2</idno>
            <idno type="stamp" n="UM-2015-2021" corresp="UNIV-MONTPELLIER">Université de Montpellier (2015-2021)</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">[Bispecific antibodies: what future?]</title>
                <author role="crp">
                  <persName>
                    <forename type="first">André</forename>
                    <surname>Pèlegrin</surname>
                  </persName>
                  <email type="md5">cef2cab8c20d33e9745fa7c723931251</email>
                  <email type="domain">inserm.fr</email>
                  <idno type="idhal" notation="string">andre-pelegrin</idno>
                  <idno type="idhal" notation="numeric">176279</idno>
                  <idno type="halauthorid" notation="string">2764-176279</idno>
                  <idno type="RESEARCHERID">http://www.researcherid.com/rid/J-3167-2016</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-9254-2648</idno>
                  <idno type="RESEARCHERID">http://www.researcherid.com/rid/http://www.researcherid.com/rid/J-3167-2016</idno>
                  <affiliation ref="#struct-55685"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Bruno</forename>
                    <surname>Robert</surname>
                  </persName>
                  <idno type="idhal" notation="numeric">755892</idno>
                  <idno type="halauthorid" notation="string">119786-755892</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-5999-4538</idno>
                  <idno type="IDREF">https://www.idref.fr/081115822</idno>
                  <affiliation ref="#struct-55685"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">21713</idno>
                <idno type="issn">0767-0974</idno>
                <idno type="eissn">1958-5381</idno>
                <title level="j">Médecine/Sciences</title>
                <imprint>
                  <publisher>EDP Sciences</publisher>
                  <biblScope unit="volume">25</biblScope>
                  <biblScope unit="issue">12</biblScope>
                  <biblScope unit="pp">1155-8</biblScope>
                  <date type="datePub">2009-12</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1051/medsci/200925121155</idno>
              <idno type="pubmed">20035697</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="fr">French</language>
            </langUsage>
            <textClass>
              <classCode scheme="halDomain" n="sdv.bio">Life Sciences [q-bio]/Biotechnology</classCode>
              <classCode scheme="halDomain" n="info.info-bt">Computer Science [cs]/Biotechnology</classCode>
              <classCode scheme="halDomain" n="sdv.can">Life Sciences [q-bio]/Cancer</classCode>
              <classCode scheme="halDomain" n="sdv.ib">Life Sciences [q-bio]/Bioengineering</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>Monoclonal antibodies have emerged as a very successful class of therapeutic agents. In their native format, monoclonal antibodies are monospecific in that they recognize only one epitope, but their Fc domain also binds to FcfR-expressing cells. Attempts to improve the cytotoxicity of antibodies, particularly in the cancer field, have led to the design of bispecific antibodies: this can occur through various strategies, such as quadroma, thioether-linked Fab' gamma fragments or genetic engineering. Such bispecific antibodies have been developped to enhance immunotherapy, by bridging tumor cells and T cells, or radioimmunotherapy by combining bispecific antibodies and radiolabeled bivalent haptens that bind cooperatively to target cells. Multiple further applications can be envisaged such as targeting two different antigens on the same cell, or two epitopes of the same antigen. Although progresses have been slowed by technical constraints, there is little doubt that this class of novel antibodies derivatives will experience a promising development. double dagger.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-55685" status="OLD">
          <orgName>Institut de recherche en cancérologie de Montpellier</orgName>
          <orgName type="acronym">IRCM - U896 Inserm - UM1</orgName>
          <date type="start">2008-01-01</date>
          <date type="end">2014-12-31</date>
          <desc>
            <address>
              <addrLine>208 rue des Apothicaires F-34298 Montpellier</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://ircm.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-42570" type="direct"/>
            <relation active="#struct-300222" type="direct"/>
            <relation name="U896" active="#struct-303623" type="direct"/>
            <relation active="#struct-410122" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-42570" status="OLD">
          <orgName>Université Montpellier 1</orgName>
          <orgName type="acronym">UM1</orgName>
          <date type="end">2014-12-31</date>
          <desc>
            <address>
              <addrLine>5, boulevard Henri IV - CS 19044 - 34967 Montpellier cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-montp1.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-300222" status="VALID">
          <orgName>CRLCC Val d'Aurelle - Paul Lamarque</orgName>
          <desc>
            <address>
              <addrLine>34298 Montpellier</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.valdaurelle.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-303623" status="VALID">
          <idno type="IdRef">026388278</idno>
          <idno type="ROR">https://ror.org/02vjkv261</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>
            <address>
              <addrLine>101, rue de Tolbiac, 75013 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-410122" status="OLD">
          <idno type="ISNI">0000000120970141</idno>
          <idno type="ROR">https://ror.org/051escj72</idno>
          <orgName>Université de Montpellier</orgName>
          <orgName type="acronym">UM</orgName>
          <date type="end">2021-12-31</date>
          <desc>
            <address>
              <addrLine>163 rue Auguste Broussonnet - 34090 Montpellier</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.umontpellier.fr/</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>